Citius Oncology Reports 78% QoQ Growth in New Institutions Ordering LYMPHIR
CTXR sits 37% above its 52-week low of $0.469.
Summary
Citius Oncology reported a 78% quarterly increase in new institutions ordering LYMPHIR, signaling strong early commercial adoption of its recently launched cancer therapy. The update provides a critical positive data point for Citius Pharmaceuticals, which faces a going-concern warning and cash constraints.
Key Events · Product Development and Regulatory · CTXR
-
78% QoQ Growth in New Institutions
New institutional accounts ordering LYMPHIR increased 78% during the quarter ended June 30, 2026, compared to the prior quarter, with total vial orders rising 31%.
-
LYMPHIR Now in 42 Institutions
The therapy is available in 42 institutions, including academic oncology centers and NCCN facilities, with more than 20 additional institutions expected in the current quarter.
-
Near-Universal Payer Coverage Secured
LYMPHIR has achieved near-universal payer coverage, complementing formulary inclusion and expanding patient access.
-
$400M+ Initial Market Opportunity
Management estimates the initial CTCL market for LYMPHIR exceeds $400 million, with the company targeting formulary inclusion at 100 priority institutions by year-end.
Analysis · CTXR · Life Sciences
Citius Oncology, the majority-owned subsidiary of Citius Pharmaceuticals, disclosed strong commercial traction for its recently launched cancer therapy LYMPHIR. New institutional accounts ordering the drug jumped 78% quarter-over-quarter, with total vial orders up 31%. The product is now available in 42 institutions, and near-universal payer coverage has been secured. Management estimates the initial CTCL market exceeds $400 million and is targeting formulary inclusion at 100 priority centers by year-end. This update comes against a backdrop of a going-concern warning and recent dilutive financing, making early commercial success critical to the company's survival. The revenue ramp, while early, provides a tangible path toward addressing cash runway concerns.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTXR was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.1M. The 52-week trading range was $0.47 to $2.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.